



MPL tablets arrive in Melbourne for Motor Neuron Disease Clinical Trial

- cGMP MPL tablet one month accelerated stability data show correct specification
- Medical monitor and clinical trial site negotiations near completion
- Clinical Site Governance conditionally approved
- Motor neuron trial remains on track for May 2022 commencement

16 May 2022 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAO), a clinical-stage biotechnology company, is pleased to announce the arrival of its cGMP (current Good Manufacturing Practice) grade monepantel (MPL) tablets specifically designed for the MND trial in Melbourne. The trial is being funded with support from FightMND.

The cGMP MPL tablets for MND were designed with a different shape and size to help swallowing by MND patients and to reach specific blood drug levels targeted for this disease. Pre-release technical specifications of the MPL tablets demonstrate that stability specification required for the trial is achieved and PharmAust is now awaiting signed technical documentation from the manufacturer.

Paperwork for shipment of the contingency/back-up second consignment is completed and these MPL tablets are on route with expected arrival later this week.

Auxiliary preparations for MND trial commencement are mostly complete except for some technical and regulatory sign-offs and characterisation of a minor impurity in the tablet, all expected to be finalised prior to the end of May. Recruitment cannot commence until final governance signature, as this is when the Clinical Trials Notification Licence with the Therapeutics Goods Administration becomes activated.

PharmAust's Chief Scientific Officer Dr Richard Mollard stated, "It is a terrific milestone to have MPL tablets designed specifically for this trial on-site. With the remaining preparations near completion, discussions with potential accruals will be formally commenced once hospital governance is signed. We are grateful to FightMND for \$881 085 funding for this trial and for its continual support."

This announcement is authorised by the Board.

Enquiries:

Dr Roger Aston
Executive Chairman
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
rmollard@pharmaust.com

P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com

About PharmAust Limited

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company that generated \$2.2 million in sales of goods & services in FY 2021.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.

About FightMND

Founded in 2014, FightMND was established in Australia with the purpose of finding effective treatments and ultimately a cure for Motor Neuron Disease (MND), also referred to as ALS or Lou Gehrig's Disease. FightMND, with its vision of a world without MND, is the largest independent funder of MND research in Australia. Since 2014, FightMND has investment more than \$63 million into MND research and care equipment to improve the lives of those fighting the disease. FightMND is determined to help facilitate the translation of the growing body of new knowledge about the disease into a cure for MND patients in Australia and abroad. For more information about FightMND, visit the website at <https://fightmnd.org.au>.